CTOs on the Move

Arsanis Inc

www.arsanis.com

 
Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.arsanis.com
  • 890 Winter Street Suite 230
    Waltham, MA USA 02451
  • Phone: 781.819.5704

Executives

Name Title Contact Details

Funding

Arsanis Inc raised $45.5M on 04/26/2017

Similar Companies

CellMax Life

CellMax Life is revolutionizing early cancer detection, prevention and management.

BioAssay Works

BioAssay Works is a Ijamsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Parental Therapy Associates

Parental Therapy Associates is a Altamonte Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AllStripes

AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data. AllStripes was founded by CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 2. The company is backed by Lux Capital, JAZZ Venture Partners, Spark Capital, Medidata Solutions, McKesson Ventures, Maveron, and a number of angel investors.

Shiru

Shiru is in the vanguard of startups that are discovering the molecular blueprints of nature — then using new ways to reconstruct the world`s most popular and pleasing ingredients without the need for animals or other unsustainable sources.